- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04217018
MR Based Prediction of Molecular Pathology in Glioma Using Artificial Intelligence
February 5, 2021 updated by: Zhenyu Zhang, The First Affiliated Hospital of Zhengzhou University
MR Based Prediction of Molecular Biomarkers or Subgroups in Primary Glioma Using Deep Learning or Machine Learning
This registry aims to collect clinical, molecular and radiologic data including detailed clinical parameters, molecular pathology (1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations, etc) and conventional/advanced/new MR sequences (T1, T1c, T2, FLAIR, ADC, DTI, PWI, etc) of patients with primary gliomas.
By leveraging artificial intelligence, this registry will seek to construct and refine algorithms that able to predict molecular pathology or subgroups of gliomas.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Non-invasive and precise prediction for molecular biomarkers such as 1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations is challenging.
With the development of artificial intelligence, much more potential lies in the preoperative conventional/advanced MR imaging (T1 weighted imaging, T2 weighted imaging, FLAIR, contrast-enhanced T1 weighted imaging, diffusion-weighted imaging, and perfusion imaging) could be excavated to aid prediction of molecular pathology of gliomas.
The creation of a registry for primary glioma with detailed molecular pathology, radiological data and with sufficient sample size for deep learning (>1000) provide considerable opportunities for personalized prediction of molecular pathology with non-invasiveness and precision.
Study Type
Observational
Enrollment (Anticipated)
3000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Zhenyu Zhang, Dr.
- Phone Number: +86 17839973727
- Email: fcczhangzy1@zzu.edu.cn
Study Locations
-
-
Henan
-
Zhengzhou, Henan, China, 450052
- Recruiting
- Department of Neurosurgery, First Affiliated Hospital of Zhengzhou University
-
Contact:
- Zhenyu Zhang, Dr.
- Phone Number: +86 17839973727
- Email: fcczhangzy1@zzu.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 95 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Patients with newly diagnosed glioma that receive tumor resection
Description
Inclusion Criteria:
- Patients must have radiologically and histologically confirmed diagnosis of primary glioma
- Life expectancy of greater than 3 months
- Must receive tumor resection
- Signed informed consent
Exclusion Criteria:
- No gliomas
- No sufficient amount of tumor tissues for detection of molecular pathology
- Patients who have any type of bioimplant activated by mechanical, electronic, or magnetic devices
- Patients who are pregnant or breast feeding
- Patients who are suffered from severe systematic malfunctions
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC of prediction performance
Time Frame: up to 10 years
|
AUC=sensitivity+specificity-1
|
up to 10 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2017
Primary Completion (Anticipated)
January 1, 2027
Study Completion (Anticipated)
June 1, 2027
Study Registration Dates
First Submitted
December 30, 2019
First Submitted That Met QC Criteria
December 31, 2019
First Posted (Actual)
January 3, 2020
Study Record Updates
Last Update Posted (Actual)
February 8, 2021
Last Update Submitted That Met QC Criteria
February 5, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GliomaAI-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
IPD Plan Description
Undecided.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioma
-
Children's Hospital of PhiladelphiaBlue Earth Diagnostics; Dragon Master FoundationNot yet recruitingGlioma | Low-grade Glioma | Glioma, Malignant | Low Grade Glioma of Brain | Glioma IntracranialUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI); Food and Drug Administration (FDA)Active, not recruitingRecurrent Glioblastoma | Recurrent Malignant Glioma | Refractory Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | Refractory Glioblastoma | Refractory WHO Grade II Glioma | Refractory WHO Grade III GliomaUnited States
-
Children's Hospital of PhiladelphiaBlue Earth Diagnostics, Inc; Dragon Master FoundationRecruitingGlioma | High Grade Glioma | Glioma, Malignant | Diffuse Glioma | Glioma IntracranialUnited States
-
ChimerixActive, not recruitingGlioblastoma | Diffuse Midline Glioma | H3 K27M Glioma | Thalamic Glioma | Infratentorial Glioma | Basal Ganglia GliomaUnited States
-
University of California, San FranciscoBeiGene USA, Inc.; Pacific Pediatric Neuro-Oncology ConsortiumRecruitingGlioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent WHO Grade III Glioma | WHO Grade III Glioma | IDH2 Gene Mutation | IDH1 Gene Mutation | Low Grade Glioma | Recurrent WHO Grade II Glioma | WHO Grade II GliomaUnited States
-
National Cancer Institute (NCI)RecruitingGlioma | High Grade Glioma | Malignant Glioma | Gliomas | Low Grade GliomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGlioblastoma | Malignant Glioma | WHO Grade III Glioma | Recurrent Glioma | Refractory GliomaUnited States
-
Beijing Tiantan HospitalDuke UniversityUnknownGlioblastoma | High Grade Glioma | Glioma, Malignant | Glioma of BrainstemChina
-
Hospital del Río HortegaCompletedGlioma | Glioblastoma | Low-grade Glioma | Glioma, Malignant | High-grade GliomaSpain
-
Sabine Mueller, MD, PhDPacific Pediatric Neuro-Oncology ConsortiumRecruitingGlioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent Grade III Glioma | Grade III GliomaUnited States, Australia, Israel, Switzerland
Clinical Trials on Prediction of molecular pathology
-
The First Affiliated Hospital of Zhengzhou UniversitySun Yat-sen UniversityRecruiting
-
The First Affiliated Hospital of Zhengzhou UniversitySun Yat-sen UniversityUnknown
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH); National... and other collaboratorsRecruiting
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
Chelsea and Westminster NHS Foundation TrustUnknownDepression | Anxiety | Uncertain Viability of Pregnancy
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
The First Affiliated Hospital of Zhengzhou UniversityRecruitingGlioma | Molecular Sequence Variation | Genetic ChangeChina
-
Second Affiliated Hospital of Nanchang UniversityWuhan University; Renmin Hospital of Wuhan UniversityRecruitingLiquid Biopsy | Deep Learning | Glioma (Diagnosis)China
-
Laura KennedyNational Cancer Institute (NCI)SuspendedBreast Cancer | Triple-negative Breast CancerUnited States
-
Ying WangRecruiting